New Data: NanoImprove Bioavailability, Drug Loads, And Pill Burdens Of Your Solid Dispersions

In recent years, amorphous solid dispersions (ASDs) have been instrumental in improving the bioavailability of many poorly water-soluble drugs. However, the high excipient content of ASDs often leads to large pill sizes and burdensome dosing regimens.

Nanoforming offers a potential solution to these challenges. New research demonstrates that nanoformed formulations can outperform ASDs in terms of bioavailability, dosage, and patient convenience. For instance, a single 160 mg nanoformed enzalutamide tablet has shown comparable efficacy to four 40 mg Xtandi tablets (an ASD formulation).

Key Learning Objectives:

• Understand the limitations of current ASD formulations.
• Explore the benefits of nanoforming as a greener alternative to ASDs.
• Examine case studies showcasing the superior performance of nanocrystals over ASDs.